[Effectiveness of bisphosphonate administration during Gn-RH agonist therapy for endometriosis].

article OA: closed CC0
View on OpenAlex View on PubMed

Abstract

Gn-RH agonist therapy is widely used for treatment of endometriosis. However, it is well known that there are some side effects due to too much suppress of plasma sex steroid hormone levels. The decrease of the BMD (bone mineral density) is a serious side effect, and the BMD values are decreasing significantly even in the short period during Gn-RH agonist therapy. In this review, the author shows the effect of bisphosphonate administration on the prevention of the bone loss during Gn-RH agonist therapy for the endometriosis. By the administration of EP (estrogen-progestogen) preparations, the decreasing of the BMD can prevent (so called add-back therapy), however, there are some patients who could not be administrated these drugs because of their previous diseases. Bisphosphonate administration is much effective for the prevention of the bone loss compared with EP preparations. From these results, it is concluded that bisphosphonate administration has a beneficial effect for the prevention of the bone loss during Gn-RH agonist treatment.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Bone Density Conservation Agents Diphosphonates Endometriosis Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Osteoporosis Osteoporosis Bone Density Bone Density Conservation Agents Diphosphonates Endometriosis Estrogen Replacement Therapy Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Osteoporosis Osteoporosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-18T06:15:08.409253+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:14:05.573375+00:00
License: CC0 · commercial use OK